Breakthrough CD7 CAR-T Cell Therapy Shows Promise for T-ALL Patients

The National University Health System in Singapore has announced groundbreaking results from a novel CAR-T cell therapy targeting CD7, offering new hope for patients with relapsed or refractory T-cell acute lymphoblastic leukaemia (T-ALL). This innovative treatment, developed in partnership with the National University of Singapore, modifies patients’ T cells to enhance immune responses against cancer cells, showing promising outcomes in clinical trials. With the potential to improve survival rates and quality of life, this therapy represents a significant advancement in precision medicine for aggressive leukaemia.